CEFTRIAXONE

NAME OF CLASSIFICATIO MECHSNISM INDICATION CONTRAINDICATION ADVERSE EFFECTS NURSING

DRUG N OF ACTION RESPONSIBILITIES
GENERIC Third Exert Third- Contraindicated to  GI: nausea, Before:
NAME: Generation bactericidal generation patients with vomiting, 1. Assess for the
Ceftriaxon Cephalosporins and cephalosporin  Hypersensitivit diarrhea, cautions and
e bacteriostati s are effective y to anorexia, contraindications
c effects by against all of Ceftriaxone abdominal (e.g. drug
TRADE interfering the previously  Hemolytic pain, allergies, CNS
NAME: Functional with the cell- mentioned Anemia flatulence depression, cv
Rocephin Classification: wall building strains. They  Liver problems  CNS: disorders, etc.) to
Antibiotics ability of are relatively  Disease of the headache, prevent any
PATIENT’S bacteria weak against gall bladder dizziness, untoward
DOSE: during cell gram-positive  Severe renal lethargy, complications.
250 mg division. bacteria but impairement paresthesia 2. Perform a
Therefore, are more  Nephrotoxicity thorough physical
ROUTE: they prevent potent against in patients assessment
IM the bacteria gram-negative who have (other
from bio bacilli, as well predisposing medications
synthesizing as renal taken, CNS, skin,
the S.marcescens insufficiency respirations, and
framework  Superinfection laboratory tests
of their cell s like renal
walls.  Phlebitis and functions tests
local abscess and complete
at the site of blood count or
IM injection CBC).
and/or IV 3. Perform culture
administration and sensitivity
. tests at the site of
infection to
ensure
appropriate use
 of the drug.
4. Conduct
orientation and
reflex
assessment, as
well as auditory
testing to
evaluate any CNS
effects of the
drug
(aminoglycosides)
.
During:
1. Check culture and
sensitivity
reports.
2. Ensure that
patient receives
full course.
3. Monitor infection
site and
presenting signs
and symptoms
throughout
course of drug
therapy.
4. Provide safety
measures to
protect the
patient if CNS
effects (e.g.
confusion,
disorientation,
numbness) occur.
 5. Educate client on
drug therapy to
promote
understanding
and compliance.
6. Provide the
following patient
teaching: safety
precautions (e.g.
changing
positions,
avoiding
hazardous tasks,
ec.), drinking lots
of fluids and to
maintain
nutrition even
though nausea
and vomiting may
occur, report
difficulty
breathing, severe
headache, fever,
diarrhea, and
signs of infection.
After:
1. Monitor patient
response to
therapy
(decrease in signs
and symptoms of
infection).
2. Monitor for
adverse effects
 (e.g. orientation
and affect,
hearing changes,
bone marrow
suppression,
renal toxicity,
hepatic
dysfunction, etc).
3. Evaluate patient
understanding on
drug therapy by
asking patient to
name the drug,
its indication, and
adverse effects to
watch for.
4. Monitor patient
compliance to
drug therapy

DOXYCYCLINE
 NAME OF CLASSIFICATIO MECHSNISM INDICATION CONTRAINDICATI ADVERSE EFFECTS NURSING
DRUG N OF ACTION ON RESPONSIBILITIES
GENERIC Tetracycline Inhibit protein  Treatment of Contraindicated to  GI: nausea, Before:
NAME: synthesis infections patient with: vomiting, 1. Assess for the
Doxycyclin leading to caused by  Liver diarrhea, cautions and
e inability of susceptible disease abdominal contraindication
Functional the bacteria strains:  History of pain, glossitis, s (e.g. drug
TRADE Classification: to multiply. Ricketssiae, yeast dysphagia, allergies, CNS
NAME: Antibiotic The affected M.pneumoni infection fatal depression, cv
Doryx protein is ae,  Kidney hepatotoxicit disorders, etc.)
similar to B.recurrentis, disease y to prevent any
PATIENT’S protein found H.influenzae, diarrhea  Skeletal and untoward
DOSE: in human cells H.ducreyi, by bones: complications.
100mg so these Bacteroides antibiotic weakening 2. Perform a
drugs can be spp., use the structure thorough
toxic to V.comma,  History of and causing physical
ROUTE: humans at Shigella spp., Lupus staining and assessment
PO high D.pneumonia  Porphyria pitting of (other
concentration e, and  Myastheni teeth and medications
s. S.aureus. a Gravis bones taken, CNS,
 Adjunct in  Dermatologic skin,
treatment of al: respirations,
protozoal photosensitivi and laboratory
infections. ty and rash tests like renal
 Superinfectio functions tests
n and complete
 Local: pain blood count or
and stinging CBC).
with topical 3. Perform culture
or ocular and sensitivity
applications tests at the site
 Hematologic: of infection to
hemolytic ensure
anemia, bone appropriate use
 marrow of the drug.
depression 4. Conduct
 Hypersensitivi orientation and
ty reactions: reflex
urticaria, assessment, as
anaphylaxis well as auditory
 Intracranial testing to
hypertension evaluate any
CNS effects of
the drug
(aminoglycoside
s).
During:
1. Check culture
and sensitivity
reports.
2. Ensure that
patient receives
full course.
3. Monitor
infection site
and presenting
signs and
symptoms
throughout
course of drug
therapy.
4. Provide safety
measures to
protect the
patient if CNS
effects (e.g.
confusion,
disorientation,
 numbness)
occur.
5. Educate client
on drug therapy
to promote
understanding
and compliance.
6. Provide the
following
patient
teaching: safety
precautions
(e.g. changing
positions,
avoiding
hazardous
tasks, ec.),
drinking lots of
fluids and to
maintain
nutrition even
though nausea
and vomiting
may occur,
report difficulty
breathing,
severe
headache,
fever, diarrhea,
and signs of
infection.
After:
1. Monitor patient
response to
 therapy
(decrease in
signs and
symptoms of
infection).
2. Monitor for
adverse effects
(e.g. orientation
and affect,
hearing
changes, bone
marrow
suppression,
renal toxicity,
hepatic
dysfunction,
etc).
3. Evaluate patient
understanding
on drug therapy
by asking
patient to name
the drug, its
indication, and
adverse effects
to watch for.
4. Monitor
patient
compliance to
drug therapy.

METRONIDAZOLE
 NAME OF CLASSIFICATIO MECHSNISM INDICATIO CONTRAINDICATION ADVERSE EFFECTS NURSING
DRUG N OF ACTION N RESPONSIBILITIES
GENERIC Functional Inhibit DNA Treatment Contraindicated to  CNS: Before:
NAME: Classification: synthesis in of patients with headache, 1. Assess for the
Metronidazol Antiprotozoal susceptible infections  Hypersensitivit dizziness, cautions and
e protozoa, caused by y to ataxia, loss of contraindication
interfering susceptible Metronidazole coordination, s (e.g. drug
TRADE NAME: with the protozoa  During first peripheral allergies,
Flagyl cell’s ability trimester of neuropathy hepatorenal
to pregnancy  GI: nausea, impairment,
PATIENT’S reproduce, vomiting, pregnancy and
DOSE: subsequentl diarrhea, lactation, etc.)
500 mg y leading to unpleasant 2. Perform a
cell death. taste, cramps, thorough
ROUTE: changes in physical
PO liver function assessment
 Superinfectio (other
n medications
taken, reflexes,
and muscle
strength, skin
and mucous
membrane,
color,
temperature,
texture, etc).
3. Assess the
patient’s liver
function,
including liver
function tests.
4. Obtain culture to
determine the
exact protozoal
 species.
5. Arrange for
appropriate
culture and
sensitivity tests
before beginning
therapy.

During:
1. Administer the
complete course
of the drug
2. Monitor hepatic
function before
adn periodically
during treatment
3. Provide comfort
measures if CNS
effects occur
(e.g. side rails
and assitance
with ambulation
if dizziness and
weakness are
present) to
prevent injury
4. Provide oral
hygiene and
ready access to
bathroom
facilities as
needed to cope
with GI effects
5. Educate client on
 drug therapy
After:
1. Monitor patient
response to
therapy
(resolution of
infection and
negative cultures
for parasite).
2. Monitor for
adverse effects
(e.g. orientation
and affect,
nutritional state,
skin, color and
lesions, hepatic
function and
occurence of
superinfections,
etc).
5. Evaluate patient
understanding
on drug therapy
by asking patient
to name the
drug, its
indication, and
adverse effects
to watch for.
6. Monitor patient
compliance to
drug therapy